HKT288X
Total Payments
$39,104
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $10,854 | 1 | 0 |
| 2017 | $28,250 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39,104 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION AND EXPANSION STUDY OF HKT288 ADMINISTERED INTRAVENOUSLY IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING EPITHELIAL OVARIAN CANCER AND RENAL CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $39,104 | 0 |
Top Doctors Receiving Payments for HKT288X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $39,104 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $39,104
- Total Doctors 0
- Transactions 2
About HKT288X
HKT288X is a drug associated with $39,104 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $10,854 was paid across 1 transactions to 0 doctors.
The most common payment nature for HKT288X is "Unspecified" ($39,104, 100.0% of total).
HKT288X is associated with 1 research study, including "A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION AND EXPANSION STUDY OF HKT288 ADMINISTERED INTRAVENOUSLY IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING EPITHELIAL OVARIAN CANCER AND RENAL CELL CARCINOMA" ($39,104).